Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | ALPI | P09923 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
| ▸ | XIAP | P98170 | 1/20 | 0.45 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.45 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA7 | P43166 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | PLAU | P00749 | 1/20 | 0.41 |
| ▸ | HPN | P05981 | 1/20 | 0.41 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | ANPEP | P15144 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL927264 | 0.88 | ALPI (0.46) | GAAALPIPKMPTGS1XIAP | |
| SCHEMBL27084167 | 0.85 | GAA (0.44) | GAAALPIPKMPTGS1XIAP | |
| SCHEMBL789966 | 0.85 | GAA (0.44) | GAAALPIPKMPTGS1XIAP | |
| SCHEMBL3939051 | 0.81 | GAA (0.44) | GAAALPIPKMPTGS1XIAP | |
| SCHEMBL11024971 | 0.79 | GAA (0.44) | GAAALPIPKMPTGS1XIAP | |
| Phenylalanine SCHEMBL18191186 | 0.76 | SLC7A5 (0.63) | GAAALPIPKMPTGS1XIAP | |
| Dl-Phenylalanine SCHEMBL18191199 | 0.76 | SLC7A5 (0.63) | GAAALPIPKMPTGS1XIAP | |
| Dl-Phenylalanine SCHEMBL28023088 | 0.76 | SLC7A5 (0.63) | GAAALPIPKMPTGS1XIAP | |
| Phenylalanine SCHEMBL10429981 | 0.76 | SLC7A5 (0.63) | GAAALPIPKMPTGS1XIAP | |
| SCHEMBL27752802 | 0.75 | MMP9 (0.48) | GAAALPIPKMPTGS1XIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230293573-A1 | OHPP-FORMULATED NICLOSAMIDE TO TREAT SARS-COV-2, OTHER VIRAL DISEASES, AND CANCERS | PURDUE RESEARCH FOUNDATION (US) | 2023-09-21 | — | — | US | disclosed |
| US-10221152-B2 | Usage of mycophenolate mofetil or salt thereof in preparing drug for resisting against influenza virus | GIANT FORCE TECHNOLOGY CORPORATION (TW) | 2019-03-05 | — | — | US | disclosed |
| CN-103479758-B | Sanguisorba officinalis-containing anti-influenza virus pharmaceutical composition | 李安荣 | 2018-02-16 | — | — | CN | disclosed |
| CN-105246484-B | Application of mycophenolate mofetil or salts thereof in preparing anti-influenza virus medicine | 当代绿能科技股份有限公司 | 2017-04-12 | — | — | CN | disclosed |
| US-20160052905-A1 | USAGE OF MYCOPHENOLATE MOFETIL OR SALT THEREOF IN PREPARING DRUG FOR RESISTING AGAINST INFLUENZA VIRUS | GIANT FORCE TECHNOLOGY CORPORATION (TW) | 2016-02-25 | — | — | US | disclosed |
| CN-105246484-A | Application of mycophenolate mofetil or salts thereof in preparing anti-influenza virus medicine | GIANT FORCE TECHNOLOGY CORP | 2016-01-13 | — | — | CN | disclosed |
| CN-103479758-A | Sanguisorba officinalis-containing anti-influenza virus pharmaceutical composition | LEE AN-RONG | 2014-01-01 | — | — | CN | disclosed |
| US-8414938-B2 | Schisandrae fructus extracts for inhibition or prevention of H1N1 influenza virus infection and its application thereof | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2013-04-09 | — | — | US | disclosed |
| US-20120189719-A1 | SCHISANDRAE FRUCTUS EXTRACTS FOR INHIBITION OR PREVENTION OF H1N1 INFLUENZA VIRUS INFECTION AND ITS APPLICATION THEREOF | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2012-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10221152-B2 | Usage of mycophenolate mofetil or salt thereof in preparing drug for resisting against influenza virus | DUSP5, DUSP4, DUSP15 | GAA 1732/4885ALPI 272/4885PKM 2635/4885 |
| US-20230293573-A1 | OHPP-FORMULATED NICLOSAMIDE TO TREAT SARS-COV-2, OTHER VIRAL DISEASES, AND CANCERS | ACE2, TMPRSS2, ACE | GAA 2949/4885ALPI 1054/4885PKM 4277/4885 |
| US-20120189719-A1 | SCHISANDRAE FRUCTUS EXTRACTS FOR INHIBITION OR PREVENTION OF H1N1 INFLUENZA VIRUS INFECTION AND ITS APPLICATION THEREOF | ENGASE, ST3GAL3, NEU1 | GAA 729/4885ALPI 2104/4885PKM 2407/4885 |
| US-20160052905-A1 | USAGE OF MYCOPHENOLATE MOFETIL OR SALT THEREOF IN PREPARING DRUG FOR RESISTING AGAINST INFLUENZA VIRUS | DUSP5, DUSP4, DUSP15 | GAA 1732/4885ALPI 272/4885PKM 2635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.